Arrowhead Pharmaceuticals makes $267 million public stock offering
168938
post-template-default,single,single-post,postid-168938,single-format-standard,bridge-core-1.0.5,tribe-no-js,tribe-bar-is-disabled,ajax_fade,page_not_loaded,,qode_grid_1300,footer_responsive_adv,hide_top_bar_on_mobile_header,qode-content-sidebar-responsive,qode-child-theme-ver-1.0.0,qode-theme-ver-18.1,qode-theme-bridge,qode_header_in_grid,wpb-js-composer js-comp-ver-6.0.2,vc_responsive
 

Arrowhead Pharmaceuticals makes $267 million public stock offering

Arrowhead Pharmaceuticals makes $267 million public stock offering

Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals is at University Research Park, Madison – STATE JOURNAL ARCHIVES

A $267 million stock offering last week by Arrowhead Pharmaceuticals, which has its main employment base in Madison, could help the company bring experimental drugs to market and lead to the purchase of other businesses.

Arrowhead — based in Pasadena, California — has 110 of its 150 employees at University Research Park on Madison’s West Side.

READ FULL STORY